

# Press Release

Regulated information

## DISCLOSURE OF RECEIVED NOTIFICATION

Waregem (Belgium) / Rotterdam (The Netherlands)<sup>1</sup>, 29 July 2011 (6.30 pm) – Pursuant to the Belgian law of 2 May 2007 relating to the disclosure of major shareholdings in listed companies, Arseus received a joint notification on 26 July 2011 from Alychlo NV, Couckinvest NV and Marc Coucke in connection with the acquisition or disposal of shares with voting rights. Couckinvest NV is controlled by Alychlo NV. Alychlo NV is controlled by Marc Coucke.

The shareholding of Couckinvest NV in Arseus decreased on 18 July 2011 from 3,451,248 shares to 0 shares. The shareholding of Alychlo NV in Arseus increased on 18 July 2011 from 0 shares to 3,451,248 shares. Marc Coucke's shareholding in Arseus remained unchanged at 76,832 shares.

Marc Coucke also holds 50,000 warrants in Arseus NV.

Based on the denominator of 31,216,888 (total number of voting rights) and the relevant notifications received by Arseus, today the shareholder structure of Arseus is as follows:

	Number of shares	% of total
EnHold NV	8,166,908	26.16%
Alychlo NV/Coucke	3,528,080	11.30%
BNP Paribas Investment Partners SA	1,546,052	4.95%
Arseus NV	1,105,585	3.54%
Public	16,870,263	54.05%

The original notification forms are also available on the corporate website of Arseus ([www.arseus.com](http://www.arseus.com)).

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

---

<sup>1</sup> This press release was sent out by Arseus NV and Arseus BV.

**For more information:**

Constantijn van Rietschoten

Director of Corporate Communications

+31 88 33 11 222 (office)

+31 6 536 91 585 (mobile)

[constantijn.van.rietschoten@arseus.com](mailto:constantijn.van.rietschoten@arseus.com)

**Arseus Profile**

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in Europe, the US and Brazil. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions.

The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.